Ensysce Biosciences (NASDAQ: ENSC) has taken a significant strategic step toward becoming a broader pain therapeutics company with the acquisition of clinical-stage Cy Biopharma, bringing together two distinct approaches to addressing one of healthcare's largest unmet needs. The transaction is backed by up to $77 million in financing and positions the combined company to advance both a next-generation non-opioid pain therapy and Ensysce's proprietary abuse-resistant opioid platform.